Aptevo Regains Rights to Prostate Cancer Therapy APVO414, Whose Results Improve After Delivery Method Tweaked

Aptevo Regains Rights to Prostate Cancer Therapy APVO414, Whose Results Improve After Delivery Method Tweaked
Aptevo Therapeutics has ended its partnership with MorphoSys AG for the development and commercialization of APVO414 as a treatment for metastatic castration resistant prostate cancer, or  mCRPC. The termination means the company has regained the worldwide rights to APVO414, which it will continue evaluating in an ongoing Phase 1 clinical trial of the therapy's safety and effectiveness, and patients' ability to tolerate it. Aptevo said switching participants' treatment regimen in the ongoing trial has led to better results than in the initial Phase 1 trial. Participants are producing fewer anti-drug antibodies -- which neutralize the therapy's effectiveness -- under the new regimen than the old one. “We’re encouraged by the latest preliminary data from the ongoing Phase 1 clinical study of APVO414,” Dr. Scott Stromatt, senior vice president of Aptevo, said in a press release. “The data suggest that administration of APVO414 by continuous infusion, rather than weekly intravenous (IV) dosing, is effective at reducing the titer [amount] of anti-drug antibodies (ADA) previously observed in the initial weekly IV dosing cohorts.” The ongoing trial (NCT02262910) is still recruiting participants. Researchers are trying to identify the maximum dose of APVO414 that patients can tolerate. In the second stage, they will be evaluating  APVO414's ability to trigger an immune response, its effect
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *